141.00
-1.00
(-0.70%)
At close: April 17 at 8:03:52 AM GMT+2
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 15 | 10 | 12 | 11 |
| Avg. Estimate | 10.05B | 10.16B | 41.21B | 43.19B |
| Low Estimate | 9.76B | 9.93B | 40.09B | 42.04B |
| High Estimate | 10.31B | 10.47B | 42.36B | 44.21B |
| Year Ago Sales | 9.4B | 9.51B | 39.11B | 41.21B |
| Sales Growth (year/est) | 6.88% | 6.93% | 5.37% | 4.80% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| CFX.F | -- | -- | -- | -- |
| S&P 500 | 7.04% | 5.20% | 8.89% | 14.14% |
Upgrades & Downgrades
| Maintains | JP Morgan: Neutral to Neutral | 4/8/2025 |
| Maintains | Citigroup: Buy to Buy | 3/24/2025 |
| Maintains | Truist Securities: Buy to Buy | 3/21/2025 |
| Upgrade | Baird: Neutral to Outperform | 3/11/2025 |
| Upgrade | B of A Securities: Neutral to Buy | 2/19/2025 |
| Maintains | Truist Securities: Buy to Buy | 1/27/2025 |